National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients

National Evaluation of the Adherence to Recommendations of VTE Treatment in Cancer Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01362933

Acronym

CARMEN

Enrollment

502

Registered

2011-06-01

Start date

2011-05-31

Completion date

2012-07-31

Last updated

2015-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms, Venous Thromboembolism

Keywords

PE, DVT, SVT, LMWH, VKA, international Venous Thromboembolism Recommendations

Brief summary

Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months. International recommendations have diffused this option.It is necessary to evaluate the compliance of physicians to this treatment by measuring the number of patients with cancer treated with long term use of LMWH.

Interventions

PROCEDUREVTE treatment in cancer patient description

proportion of patients treated for evolutive VTE according to international recommendations

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

All patients with cancer present in the clinic, hospital, out patients diagnosed with a VTE during the 6 previous months. VTE can be symptomatic or asymptomatic, can be located close to a central line, and of any type (DVT, PE, SVT)

Exclusion criteria

* Patient already included in a trial studying antithrombotic therapy * Patient refusing the study * Patient under 18 and/or not competent to give informed consent

Design outcomes

Primary

Measure	Time frame	Description
Evaluation of the adherence to recommendations of VTE treatment in cancer patients	At baseline (J0)	Proportion of patients treated for evolutive VTE according to international recommandations Patients could be hospitalised or could be out patient

Secondary

Measure	Time frame	Description
Evaluation of VTE disease according to cancer diagnosis (proportion of SVT (Superficial Venous Thrombosis), DVT (Deep Venous Thrombosis), PE (Pulmonary Embolism)	At baseline (J0)	Percentage of VTE (PE,DVT,SVT)and cancer type
Proportion of asymptomatic VTE disease for this population	At baseline (J0)	percentage of VTE and cancer status (local, metastatic)
Feasibility of self injections for VTE treatment in cancer patients.	At baseline (J0)	percentage of patients practising self injections
Proportion of patients with catheter thrombosis	At baseline (J0)	Percentage of patients receiving novel cancer therapies

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026